Future developments kinase activation

One group of compounds that is of particular interest for future development is the p38 kinase inhibitors. This group is particularly interesting because of the extensive research that has described them as a potential treatment focused on inflammatory pain mechanisms. P38 kinase has long been known to play an important role in inflammation especially in joint-related pathologies. Briefly, these kinases are thought to exhibit their therapeutic benefit by inhibiting many of the pro-inflammatory cytokines such as TNFa, IL-6 and IL-ip (see Cytokine family). BMS has advanced a candidate as an orally active... 

The mechanism of action proposed is based on a direct binding to the channel and the following partial block of the ATP-binding pocket of CFTR (French et al., 1997), a mechanism similar to that used by genistein to inhibit the activity of other ATP-utilizing enzymes such as protein kinases and topoisomerase II (Polkowski and Mazurek, 2000 and refs therein). The selection of flavonoid compounds or the development of synthetic drugs reasonably selective for CFTR activation might be an area for future clinical trials. 

---